Top

International Journal of Clinical Oncology

Published in:

Open Access 01-10-2021 | Pancreatic Cancer | Review Article

Hereditary pancreatic cancer

Authors: Kodai Abe, Minoru Kitago, Yuko Kitagawa, Akira Hirasawa

Published in: International Journal of Clinical Oncology | Issue 10/2021

Abstract

Pancreatic cancer is associated with both family and hereditary cancer syndromes. Multigene panel testing for pancreatic cancer detected the germline variants BRCA1/2, PALB2, ATM, TP53, MLH1, STK11/LKB1, APC, CDKN2A, and SPINK1/PRSS1 as high-risk genes. A latest genome-wide association study revealed the common, but low-risk germline variants in pancreatic cancer patients. Active pancreatic surveillance using magnetic resonance imaging and endoscopic ultrasound is recommended for high-risk individuals who have a family history of pancreatic cancer or harbor these germline pathogenic variants to improve the detection rate and prognosis of pancreatic cancer. Since poly-ADP-ribose polymerase (PARP) inhibitor has been shown to be effective in improving the prognosis of BRCA-positive pancreatic cancer as well as hereditary breast and ovarian cancer syndrome, PARP inhibitor therapy is currently being applied as precision medicine to pancreatic cancer patients harboring the BRCA1/2 germline variant. This review highlights the importance of surveillance for germline pathogenic variants in pancreatic cancer and is expected to lead to improvements in the diagnosis and prevention of pancreatic cancer as well as facilitate the development of effective therapeutic strategies and precision medicine.

Yamaguchi K, Okusaka T, Shimizu K et al (2017) Clinical practice guidelines for pancreatic cancer 2016 from the Japan Pancreas Society. Pancreas 46(5):595–604PubMedCrossRef

McGuigan A, Kelly P, Turkington RC et al (2018) Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24(43):4846–4861PubMedPubMedCentralCrossRef

Midha S, Chawla S, Garg PK (2016) Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett 381:269–277PubMedCrossRef

Jiao L, Mitrou PN, Reedy J et al (2009) A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med 169(8):764–770PubMedPubMedCentralCrossRef

Matsubayashi H, Takaori K, Morizane C et al (2017) Familial pancreatic cancer: concept, management and issues. World J Gastroenterol 23(6):935–948PubMedPubMedCentralCrossRef

Matsubayashi H (2011) Familial pancreatic cancer and hereditary syndromes: screening strategy for high-risk individuals. J Gastroenterol 46:1249–1259PubMedCrossRef

Young EL, Thompson BA, Neklason DW et al (2018) Pancreatic cancer as a sentinel for hereditary cancer predisposition. BMC Cancer 18(697):1–9

Pittman ME, Brosens LA, Wood LD (2016) Genetic syndromes with pancreatic manifestations. Surg Pathol 9:705–715CrossRef

Rustgi AK (2014) Familial pancreatic cancer: genetic advances. Genes Dev 28:1–7PubMedPubMedCentralCrossRef

10.

Ohmoto A, Yachida S, Morizane C (2019) Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Sci. https://doi.org/10.3390/ijms20030561CrossRefPubMedPubMedCentral

11.

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71PubMedCrossRef

12.

Goggins M, Schutte M, Lu J et al (1997) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364

13.

Wong W, Raufi AG, Safyan RA et al (2020) BRCA mutations in pancreatic cancer: spectrum, current management, challenges and future prospects. Cancer Manag Res 12:2731–2742PubMedPubMedCentralCrossRef

14.

NCCN Guidelines^® genetic/familial high-risk assessment: breast, ovarian, and pancreatic version 1.2021 Pancreatic Cancer Screening (PANC-A)

15.

Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2- interacting protein, is a breast cancer susceptibility gene. Nat Genet 39(2):165–167PubMedCrossRef

16.

Abe K, Ueki A, Urakawa Y et al (2021) Familial pancreatic cancer with PALB2 and NBN pathogenic variants: a case report. Hered Cancer Clin Pract. https://doi.org/10.1186/s13053-020-00160-zCrossRefPubMedPubMedCentral

17.

Yang X, Leslie G, Doroszuk A et al (2019) Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol 38:674–685PubMedPubMedCentralCrossRef

18.

Tischkowitz M, Balmaña J, Foulkes W et al (2021) Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. https://doi.org/10.1038/s41436-021-01151-8CrossRefPubMedPubMedCentral

19.

Roberts NJ, Jiao Y, Yu J et al (2012) ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2:41–46PubMedCrossRef

20.

Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813–822PubMedCrossRef

21.

Borecka M, Zemankova P, Lhota F et al (2016) The c.657del5 variant in the NBN gene predisposes to pancreatic cancer. Gene 587:169–172PubMedCrossRef

22.

Ruijs M, Verhoef S, Rookus M et al (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421–428. https://doi.org/10.1136/jmg.2009.073429CrossRefPubMed

23.

Biller LH, Syngal S, Yurgelun MB (2019) Recent advances in Lynch syndrome. Fam Cancer 18:211–219PubMedPubMedCentralCrossRef

24.

Bujanda L, Herreros-Villanueva M (2017) Pancreatic cancer in Lynch Syndrome. J Cancer 8(18):3667–3674PubMedPubMedCentralCrossRef

25.

Seppala T, Latchford A, Negoli I et al (2020) European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. BJS. https://doi.org/10.1002/bjs.11902CrossRef

26.

Korsse SE, Harinck F, Lier MG et al (2013) Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 50:59–64PubMedCrossRef

27.

Hirasawa A, Akahane T, Tsuruta T et al (2012) Lobular endocervical glandular hyperplasia and peritoneal pigmentation associated with Peutz-Jeghers syndrome due to a germline mutation of STK11. Ann Oncol 23:2990–2994PubMedCrossRef

28.

Nakamura Y, Nishisho I, Kinzler K et al (1992) Mutations of the APC (Adenomatous Polyposis Coli) gene in FAP (Familial Polyposis Coli) patients and in sporadic colorectal tumors. Tohoku J Exp Med 168:141–147PubMedCrossRef

29.

Moussata D, Senouci L, Berger F et al (2015) Familial adenomatous polyposis and pancreatic cancer. Pancreas 44(3):512–513PubMedCrossRef

30.

Vasen H, Gruis N, Frants R et al (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma assoiated with a specific 19 deletion of p16 (p16-leiden). Int J Cancer 87:809–811PubMedCrossRef

31.

Hu C, Hart S, Polley E et al (2018) Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319(23):2401–2409. https://doi.org/10.1001/jama.2018.6228CrossRefPubMedPubMedCentral

32.

Vasen H, Ibrahim I, Ponce C et al (2016) Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34(17):2010–2019PubMedCrossRef

33.

Ishida H, Ishibashi K, Iwama T (2018) Malignant tumors associated with juvenile polyposis syndrome in Japan. Surg Today 40:253–263CrossRef

34.

Wain KE, Ellingson MS, McDonald J et al (2014) Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. Genet Med 16(8):588–593PubMedPubMedCentralCrossRef

35.

Masamune A, Kikuta K, Hamada S et al (2018) Nationwide survey of hereditary pancreatitis in Japan. J Gastroenterol 53:152–160PubMedCrossRef

36.

Tamura K, Yu J, Hata T et al (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci USA 115:4767–4772PubMedPubMedCentralCrossRef

37.

Roberts NJ, Norris AL, Petersen GM et al (2015) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6(2):166–175PubMedPubMedCentralCrossRef

38.

Chaffee KG, Oberg AL, McWilliams RR et al (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20(1):119–127PubMedCrossRef

39.

Pogue-Geile KL, Chen R, Bronner MP et al (2006) Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 3(12):2216–2228CrossRef

40.

Takai E, Nakamura H, Chiku S et al (2020) Whole-exome sequencing reveals new potential susceptibility genes for japanese familial pancreatic cancer. Ann Surg. https://doi.org/10.1097/SLA.0000000000004213CrossRef

41.

Klien A, Wolpin B, Risch H et al (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556. https://doi.org/10.1038/s41467-018-02942-5CrossRef

42.

Lin Y, Nakatochi M, Hosono Y et al (2020) Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Nat Commun. https://doi.org/10.1038/s41467-020-16711-wCrossRefPubMedPubMedCentral

43.

Friedman JM, Fialkow PJ (1976) Familial carcinoma of the pancreas. Clin Genet 9:463–469PubMedCrossRef

44.

Klein AP, Hruban RH, Brune KA et al (2001) Familial pancreatic cancer. Cancer J 7(4):266–273PubMed

45.

Hruban RH, Canto MI, Yeo CJ (2001) Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Dig Dis 19:76–84PubMedCrossRef

46.

Mocci E, Guillen-Ponce C, Earl J et al (2015) PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer 51:1911–1917PubMedCrossRef

47.

Morizane C, Kitano M, Hijioka S et al (2017) Japanese familial pancreatic cancer registry with the aim to early detection of pancreatic cancer. Suizo 32(1):23–29CrossRef

48.

Alison KP, Kieran BA, Gloria PM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Can Res 64:2634–2638CrossRef

49.

Tersmette AC, Peterson GM, Offerhaus GJ et al (2001) Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7:738–744PubMed

50.

McFaul CD, Greenhalf W, Earl J et al (2006) Anticipation in familial pancreatic cancer. Gut 55:252–258PubMedPubMedCentralCrossRef

51.

Schneider R, Slater E, Sina M et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years’ experience. Fam Cancer 11:323–330CrossRef

52.

Molina-Montes E, Gomez-Rubio P, Márquez M et al (2018) Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Int J Epidemiol 47(2):473–483PubMedCrossRef

53.

Egawa S, Toma H, Ohigashi H et al (2012) Japan pancreatic cancer registry; 30th year anniversary. Japan Pancreas Society. Pancreas 41(7):985–992PubMedCrossRef

54.

Ansari D, Bauden M, Bergström S et al (2017) Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. BJS 104:600–607CrossRef

55.

Capasso M, Franceschi M, Rodriguez-Castro KI et al (2018) Epidemiology and risk factors of pancreatic cancer. Acta Biomed 89(9):141–146PubMed

56.

Goggins M, Overbeek KA, Brand R et al (2020) Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69:7–17PubMedCrossRef

57.

Singhi AD, Koay EJ, Chan ST et al (2019) Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 156:2024–2040PubMedCrossRef

58.

Lindquist CM, Miller FH, Hammond NA et al (2018) Pancreatic cancer screening. Abdom Radiol 43:264–272CrossRef

59.

Matsubayashi H, Takaori K, Morizane C et al (2019) Familial pancreatic cancer and surveillance of high-risk individuals. Gut Liver 13(5):498–505PubMedPubMedCentralCrossRef

60.

Canto MI, Almario JA, Schulick RD et al (2018) Risk of neoplastic progression in individuals at high risk for pancreatic cancer undergoing long-term surveillance. Gastroenterol 155:740–751CrossRef

61.

Yurgelun MB, Chittenden AB, Morales-Oyarvide V et al (2019) Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med 21(1):213–223PubMedCrossRef

62.

NCCN (2020) NCCN guidelines version 1.2020 pancreatic cancer screening. NCCN (printed on 6 August 2020)

63.

Kowalewski A, Szylberg L, Saganek M et al (2018) Emerging strategies in BRCA-positive pancreatic cancer. J Cancer Res Clin Oncol 144:1503–1507PubMedPubMedCentralCrossRef

64.

Golan T, Hammel P, Reni M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. NEJM 381(4):317–327PubMedCrossRef

65.

Prescribing Information of KEYTRUDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125514s014lbl.pdf. Accessed 15 Aug 2020

66.

Ohmoto A, Yachida S, Morizane C (2019) Genomic features and clinical management of patients with hereditary pancreatic cancer syndromes and familial pancreatic cancer. Int J Mol Med 20(561):1–16

67.

Fogelman D, Sugar EA, Oliver G et al (2015) Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol 76:489–498PubMedPubMedCentralCrossRef

68.

Okano N, Morizane C, Nomura S et al (2020) Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study). Int J Clin Oncol 25(10):1835–1843PubMedCrossRef

69.

Golan T, Kanji ZS, Epelbaum R et al (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:1132–1138PubMedPubMedCentralCrossRef

70.

Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250PubMedCrossRef

71.

Shindo K, Yu J, Suenaga M et al (2017) Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 20(35):3382–3390CrossRef

72.

Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. https://doi.org/10.1038/gim.2015.30CrossRefPubMedPubMedCentral

73.

Holter S, Borgida A, Dodd A et al (2015) Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33(28):3124–3129PubMedCrossRef

74.

Mizukami K, Iwasaki Y, Kawakami E et al (2020) Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBio Med. https://doi.org/10.1016/j.ebiom.2020.103033CrossRef

75.

Abe T, Blackford A, Tamura K et al (2019) Deleterious germline mutations are a risk factor for neoplastic progression among high-risk individuals undergoing pancreatic surveillance. J Clin Oncol 37:1070–1080. https://doi.org/10.1200/JCO.18.01512CrossRefPubMedPubMedCentral

76.

Scholten L, Latenstein A, Aalfs C et al (2020) Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. UEG J 8(8):865–877CrossRef

Title: Hereditary pancreatic cancer
Authors: Kodai Abe
Minoru Kitago
Yuko Kitagawa
Akira Hirasawa
Publication date: 01-10-2021
Publisher: Springer Singapore
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: International Journal of Clinical Oncology / Issue 10/2021
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-021-02015-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2021

Radiotherapy role in non-seminomatous germ cell tumors, radiobiological and technical issues of an unexplored scenario

Outcome of patients with newly diagnosed primary CNS lymphoma after high-dose methotrexate followed by consolidation whole-brain radiotherapy and cytarabine: an 8-year cohort study

Serum zinc deficiency in patients after gastrectomy for gastric cancer

Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study

High expression of miR-195 is related to favorable prognosis in cytogenetically normal acute myeloid leukemia

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer